ATE304533T1 - Tetrahydrochinolinderivate als muscarinische agonisten - Google Patents

Tetrahydrochinolinderivate als muscarinische agonisten

Info

Publication number
ATE304533T1
ATE304533T1 AT02794441T AT02794441T ATE304533T1 AT E304533 T1 ATE304533 T1 AT E304533T1 AT 02794441 T AT02794441 T AT 02794441T AT 02794441 T AT02794441 T AT 02794441T AT E304533 T1 ATE304533 T1 AT E304533T1
Authority
AT
Austria
Prior art keywords
compounds
muscarinic agonists
methods
muscarinic receptor
tetrahydrochinoline
Prior art date
Application number
AT02794441T
Other languages
English (en)
Inventor
Niels Skjaerbaek
Kristian Norup Koch
Bo Lennart Mikael Friberg
Bo-Ragnar Tolf
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of ATE304533T1 publication Critical patent/ATE304533T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02794441T 2001-12-28 2002-12-23 Tetrahydrochinolinderivate als muscarinische agonisten ATE304533T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34472201P 2001-12-28 2001-12-28
PCT/US2002/041617 WO2003057672A2 (en) 2001-12-28 2002-12-23 Tetrahydroquinoline analogues as muscarinic agonists

Publications (1)

Publication Number Publication Date
ATE304533T1 true ATE304533T1 (de) 2005-09-15

Family

ID=23351729

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794441T ATE304533T1 (de) 2001-12-28 2002-12-23 Tetrahydrochinolinderivate als muscarinische agonisten

Country Status (19)

Country Link
US (3) US7307075B2 (de)
EP (1) EP1461318B9 (de)
JP (1) JP4509565B2 (de)
KR (1) KR100972614B1 (de)
CN (1) CN100402032C (de)
AT (1) ATE304533T1 (de)
AU (1) AU2002359875B2 (de)
BR (1) BR0215430A (de)
CA (1) CA2470578C (de)
DE (1) DE60206198T2 (de)
DK (1) DK1461318T3 (de)
ES (1) ES2251624T3 (de)
IL (2) IL162616A0 (de)
MX (1) MXPA04006281A (de)
NO (1) NO327522B1 (de)
NZ (1) NZ533566A (de)
RU (1) RU2292346C2 (de)
WO (1) WO2003057672A2 (de)
ZA (1) ZA200405024B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304533T1 (de) 2001-12-28 2005-09-15 Acadia Pharm Inc Tetrahydrochinolinderivate als muscarinische agonisten
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1613321A2 (de) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinische m1 rezeptor-agonisten für die schmerzbehandlung
EP1900732A4 (de) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd Neue nitrogenierte heterocyclische verbindung und salz davon
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607949D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008016534A1 (en) 2006-07-31 2008-02-07 Janssen Pharmaceutica, N.V. Urotensin ii receptor antagonists
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2379762T3 (es) 2008-08-02 2012-05-03 Janssen Pharmaceutica N.V. Antagonistas del receptor de la urotensina II
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4447953A1 (de) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Kombination aus muskarinrezeptor-positiven modulatoren und nmda-positiven allosterischen modulatoren

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365457A (en) * 1964-05-08 1968-01-23 Sterling Drug Inc N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
US3324137A (en) * 1964-05-08 1967-06-06 Sterling Drug Inc N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
JPS63290821A (ja) * 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JP2886570B2 (ja) * 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
US5149815A (en) * 1991-04-29 1992-09-22 American Home Products Corporation N-substituted-2-aminoquinolines
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5457099A (en) * 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
WO1997012870A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome S.P.A. Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
EP0934932A4 (de) * 1996-08-22 2002-06-26 Meiji Seika Kaisha Chinolinderivate und psychotropes mittel
US5919750A (en) * 1997-07-24 1999-07-06 Akzo Nobel Nv Fabric softener composition
IL137656A0 (en) * 1998-03-31 2001-10-31 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
CA2326804C (en) * 1998-03-31 2006-05-02 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
EP1221443B1 (de) 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
ES2302992T3 (es) * 1999-12-30 2008-08-01 H. Lundbeck A/S Derivados de 4-fenil-piperazinil, -piperidinil y tetrahidropiridil como antagonistas de dopamina d4.
ATE366249T1 (de) * 2000-02-29 2007-07-15 Mitsubishi Pharma Corp Zyklische amid-derivate
CN1814596A (zh) * 2000-04-28 2006-08-09 阿卡蒂亚药品公司 毒蕈碱性激动剂
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
ATE304533T1 (de) 2001-12-28 2005-09-15 Acadia Pharm Inc Tetrahydrochinolinderivate als muscarinische agonisten
EP1613321A2 (de) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinische m1 rezeptor-agonisten für die schmerzbehandlung

Also Published As

Publication number Publication date
RU2292346C2 (ru) 2007-01-27
EP1461318B1 (de) 2005-09-14
JP4509565B2 (ja) 2010-07-21
KR20040070287A (ko) 2004-08-06
DE60206198T2 (de) 2006-06-14
CN1635891A (zh) 2005-07-06
US20060199813A1 (en) 2006-09-07
IL162616A (en) 2011-06-30
US7576078B2 (en) 2009-08-18
EP1461318A2 (de) 2004-09-29
CA2470578A1 (en) 2003-07-17
BR0215430A (pt) 2004-12-14
ES2251624T3 (es) 2006-05-01
NZ533566A (en) 2007-03-30
MXPA04006281A (es) 2004-09-27
EP1461318B9 (de) 2005-12-28
US7576100B2 (en) 2009-08-18
CA2470578C (en) 2010-10-12
KR100972614B1 (ko) 2010-07-27
AU2002359875A1 (en) 2003-07-24
US20030176418A1 (en) 2003-09-18
AU2002359875B2 (en) 2009-01-08
WO2003057672A2 (en) 2003-07-17
US20060199810A1 (en) 2006-09-07
NO20043013L (no) 2004-07-28
DE60206198D1 (de) 2005-10-20
IL162616A0 (en) 2005-11-20
NO327522B1 (no) 2009-08-03
CN100402032C (zh) 2008-07-16
US7307075B2 (en) 2007-12-11
ZA200405024B (en) 2005-07-27
HK1074573A1 (zh) 2005-11-18
WO2003057672A3 (en) 2003-11-13
JP2005519060A (ja) 2005-06-30
DK1461318T3 (da) 2006-01-09
RU2004123203A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
ATE304533T1 (de) Tetrahydrochinolinderivate als muscarinische agonisten
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MA27933A1 (fr) Inhibiteurs de l&#39;activite de akt
NO20013443D0 (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
EA200200208A1 (ru) Синергитическая композиция
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu&#39;antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
WO2003105840A3 (en) Sphingosine kinase inhibitors
DE60033649D1 (de) Verbindungen und therapeutische methoden
DE60309057D1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE504293T1 (de) Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1461318

Country of ref document: EP